Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).
ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)
Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).
Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).